Sally S. Ong, MD, spoke with Modern Retina about her research titled, "Individual and neighborhood-level socioeconomic characteristics associated with presenting visual acuity and foveal status in rhegmatogenous retinal detachment" at the annual ASRS meeting in Stockholm, Sweden.
Companies continue to share news about the data that will be presented at the 2024 ASRS meeting in Stockholm, Sweden.
42nd Annual Meeting in Stockholm, the Venice of the North
The ASRS annual meeting will take place in Stockholm, Sweden on July 16-20, 2024. Several major updates are already anticipated at the event.
The award, supported by Oculis, will recognize outstanding contributions to retina research and will grant €30,000 for research support, and an additional €5,000 directly to the candidate.
The 2024 event was held in Seattle, Washington, from May 5 through May 9. Members of the Ophthalmology Times team attended and interviewed several researchers and industry professionals, highlighting news from the meeting.
Anat Loewenstein, MD, spoke with Modern Retina about her presentation of AXPAXLI trial results and upcoming trials for this potential treatment, which she gave at Clinical Trials at the Summit meeting held in Park City, Utah on June 8, 2024.
This retrospective real-world evaluation of the drug considered a number of important as-yet-unanswered questions.
To date, only the onset and enlargement of hyperTDs measured using en-face OCT imaging has been validated as a clinical trial endpoint.
Jennifer Lim, MD, FARVO, spoke with us about her presentation Faricimab vs aflibercept in the reduction of exudates in Y/R trials" at Clinical Trials at the Summit meeting in Park City, Utah on June 8, 2024.
Carl Danzig, MD, spoke with us about his presentation on the 24 week results of the PRISM trials for wet AMD. He gave this presentation at Clinical Trials at the Summit meeting in Park City, Utah on June 8, 2024.
Christina Weng, MD, spoke with us about her presentation on the emerging technology of home OCT and its role in AMD. She gave this presentation at Clinical Trials at the Summit meeting being held in Park City, Utah on June 8, 2024.
Michael Singer, MD, spoke with Modern Retina about his presentation of first time data from the CALM Registry at Clinical Trials at the Summit meeting being held in Park City, Utah on June 8, 2024.
Eleonora Lad, MD, PhD, discusses the stages of dry AMD from early to intermediate to geographic atrophy, while also assessing which endpoints are most useful for these different stages.
Arshad M. Khanani, MD, MA, shares what attendees and the retina community can expect from the Clinical Trials at the Summit meeting being held in Park City, Utah on June 8, 2024.
Durga Borkar, MD, MMCi, spoke with Modern Retina about the quality data (Qdata) gathered on geographic atrophy as well as the GATHER 1 and GATHER 2 data she presented at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.
Ash Abbey, MD, spoke with Modern Retina at the 2024 Retina World Congress in Fort Lauderdale, Florida. He shared details about the week 32 data from the phase 2 DAVIO-2 trial for EYP-1901.
J. Fernando Arevalo, MD, PhD, FACS, FASRS, spoke about a recent study looking at what happens to patients with diabetic retinopathy who are lost to follow-up. He presented this research at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.
David Almeida, MD, PhD, MBA, shared insights on the surgical tools he uses in his practice at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.
At this year's ARVO meeting, Edmund Tsui, MD, presented a paper on the analysis of anterior chamber inflammation through automated quantitative assessment of swept-source anterior segment OCT images.
At this year's ARVO meeting, Roger Goldberg, MD, presented a paper on hard exudates and their resolution in patients with diabetic macular edema treated with either faricimab or 2 mg aflibercept.
At this year's ARVO meeting, Daniela Ferrara, MD, PhD, FASRS, presented a paper on predicting functional outcomes for different treatment durations of faricimab in diabetic macular edema.
At this year's ARVO meeting, Irene Santiago Tierno, MS, talked with Ophthalmology Times about the paper she presented on how abnormal subendothelial matrix exacerbates choroidal endothelial cell death in early age-related macular degeneration.
Dilsher S. Dhoot, MD, shared details about the Week 52 safety and efficacy data from the US phase 1 clinical trial of sustained-release axitinib hydrogel implant (OTX-TKI) for neovascular age-related macular degeneration at the 2024 Retina World Congress meeting in Fort Lauderdale, Florida.
At this year's ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Niranchana Manivannan, PhD. She spoke about the poster presentation, "Feasibility and clinical efficacy of an OCT B-scan of interest tool."
Professor Paulo-Eduardo Stanga spoke with Modern Retina about a new wearable assistance device at the 2024 Retina World Congress meeting held in Fort Lauderdale, Florida
This year at ARVO, Emily Chew, MD, was awarded the Proctor Award Lecture. She spoke with the Eye Care Network about this lecture and what the award meant to her.
This year at ARVO, Anand Swaroop, PhD, was awarded the Friedenwald Award Lecture 2024. He spoke with the Eye Care Network about this lecture and what the award meant to him.
